Statera Biopharma Shares Fall After Taking Stake In Holographic Medical Imaging
Statera Biopharma Shares Fall After Taking Stake In Holographic Medical Imaging
Statera Biophma入股全息医学成像公司后股价下跌
- Statera Biopharma Inc (NASDAQ:STAB) signed a binding Memorandum of Understanding with Holobeam Technologies Inc.
- Holobeam offers holographic medical imaging and therapeutic technologies for early cancer detection, treatment, and other diseases using Holographic Energy Teleportation (HET) technology.
- Under the terms of the MOU, Statera will acquire a 25% interest in Holobeam for access to their technology and assist in targeting Statera drugs specifically to the site of cancer in concentrations that would not be possible under normal dosing.
- The MOU provides an exclusivity period of sixty (60) days for negotiating and finalizing a definitive agreement.
- Michael Handley, President & Chief Executive Officer of Statera, said, "Holobeam's technology also has the potential to precisely deliver focused energy to the tumor cells, thus making them more susceptible to therapeutic intervention."
- In April, Statera Biopharma entered into a non-binding term sheet with Immune Therapeutics Inc (OTC:IMUN) to sell its naltrexone and met-enkephalin rights.
- Under the anticipated terms, Statera will receive an initial $2 million upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics.
- Price Action: STAB shares are down 13.50% at $0.19 during the premarket session on the last check Tuesday.
- Statera Biophma Inc.(纳斯达克：STAB)与中国签署具有约束力的谅解备忘录全息科技公司.
- HoloBeam使用全息能量隐形传输(HET)技术为癌症早期检测、治疗和其他疾病提供全息医学成像和治疗技术。
- 根据谅解备忘录的条款，Statera将获得HoloBeam 25%的股份，以获得他们的技术，并协助针对癌症部位的Statera药物，其浓度在正常剂量下是不可能的。
- 谅解备忘录规定了六十(60)天的排他性期限，用于谈判和最终敲定最终协议。
- 斯泰拉公司首席执行官、总裁先生迈克尔·汉德利说：“全息科技公司的技术还具有向肿瘤细胞精确传递聚焦能量的潜力，从而使它们更容易受到治疗干预。”
- 在四月份，Statera Biophma签订了一份不具约束力的条款说明书免疫治疗公司(场外交易代码：IMUN)出售其纳曲酮和甲基脑啡肽的经营权。
- 根据预期的条款，Statera将获得200万美元的初始预付款以及免疫治疗公司已发行和已发行股票的5%。
- 价格行动：在周二的盘前交易中，STAB的股价下跌了13.50%，至0.19美元。